{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T21:46:45Z","timestamp":1775771205212,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To report a case series of non-infectious anterior scleritis resistant to multiple lines of conventional therapies which were eventually successfully treated with off-label subconjunctival dexamethasone implant (Ozurdex<jats:sup>\u00ae<\/jats:sup>) injection (SDI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective case series of 4 patients (6 eyes).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In the index case series, the patients had a mean age of 57.2 years (range 36 to 82 years, SD 19.2 years) with 50% being female. Two patients had underlying autoimmune diseases: rheumatoid arthritis (<jats:italic>n<\/jats:italic>\u2009=\u20091), and granulomatosis with polyangiitis (GPA) (<jats:italic>n<\/jats:italic>\u2009=\u20091). The other patients were diagnosed with idiopathic anterior scleritis after extensive systemic investigations (<jats:italic>n<\/jats:italic>\u2009=\u20092). The mean follow-up duration and the mean number of concomitant therapies prior to SDI was 27 (SD 17.7) months and 2 (SD 0.81), respectively. In all patients, symptom resolution and significant improvement in disease activity were achieved after SDI, persisting for an extended period following the resorption of the implant. No scleral melt, infection or ocular hypertension were noted following SDI.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>SDI may be a safe and effective therapeutic option for resistant non-infectious anterior scleritis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12348-025-00494-6","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T05:00:59Z","timestamp":1746507659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Subconjunctival dexamethasone implant (Ozurdex\u00ae) in the management of refractory Non-Infectious anterior scleritis"],"prefix":"10.1186","volume":"15","author":[{"given":"Battuya","family":"Ganbold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ba Trung","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Horung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azadeh","family":"Mobasserian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng Xian","family":"Thng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hashem","family":"Ghoraba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Negin","family":"Yavari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia El","family":"Feky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cigdem","family":"Yasar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aim-On","family":"Saengsirinavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances Andrea","family":"Anover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Saeed","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ngoc","family":"Tuong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trong","family":"Than","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anadi","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Elaraby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Akhavanrezayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankur Sudhir","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woong Sun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Or","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"issue":"3","key":"494_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/bjo.60.3.163","volume":"60","author":"PG Watson","year":"1976","unstructured":"Watson PG, Hayreh SS (1976) Scleritis and episcleritis. Br J Ophthalmol Mar 60(3):163\u2013191. https:\/\/doi.org\/10.1136\/bjo.60.3.163","journal-title":"Br J Ophthalmol Mar"},{"issue":"2","key":"494_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/s0161-6420(94)31325-x","volume":"101","author":"M de la Sainz","year":"1994","unstructured":"de la Sainz M, Jabbur NS, Foster CS (1994) Severity of scleritis and episcleritis. Ophthalmol Feb 101(2):389\u2013396. https:\/\/doi.org\/10.1016\/s0161-6420(94)31325-x","journal-title":"Ophthalmol Feb"},{"issue":"4","key":"494_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/s0002-9394(00)00710-8","volume":"130","author":"DA Jabs","year":"2000","unstructured":"Jabs DA, Mudun A, Dunn JP, Marsh MJ (2000) Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol Oct 130(4):469\u2013476. https:\/\/doi.org\/10.1016\/s0002-9394(00)00710-8","journal-title":"Am J Ophthalmol Oct"},{"issue":"4","key":"494_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/s0161-6420(95)30970-0","volume":"102","author":"M de la Sainz","year":"1995","unstructured":"de la Sainz M, Foster CS, Jabbur NS (1995) Scleritis associated with systemic vasculitic diseases. Ophthalmol Apr 102(4):687\u2013692. https:\/\/doi.org\/10.1016\/s0161-6420(95)30970-0","journal-title":"Ophthalmol Apr"},{"key":"494_CR5","unstructured":"C Stephen Foster MSdlM (2012) The sclera. Springer Science & Business Media"},{"issue":"3","key":"494_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ophtha.2003.06.006","volume":"111","author":"EK Akpek","year":"2004","unstructured":"Akpek EK, Thorne JE, Qazi FA, Do DV, Jabs DA (2004) Evaluation of patients with scleritis for systemic disease. Ophthalmol Mar 111(3):501\u2013506. https:\/\/doi.org\/10.1016\/j.ophtha.2003.06.006","journal-title":"Ophthalmol Mar"},{"issue":"5","key":"494_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3109\/09273948.2013.854394","volume":"22","author":"G Homayounfar","year":"2014","unstructured":"Homayounfar G, Borkar DS, Tham VM, Nardone N, Acharya NR (2014) Clinical characteristics of scleritis and episcleritis: results from the Pacific ocular inflammation study. Ocul Immunol Inflamm Oct 22(5):403\u2013404. https:\/\/doi.org\/10.3109\/09273948.2013.854394","journal-title":"Ocul Immunol Inflamm Oct"},{"issue":"4","key":"494_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.survophthal.2005.04.001","volume":"50","author":"N Okhravi","year":"2005","unstructured":"Okhravi N, Odufuwa B, McCluskey P, Lightman S, Scleritis (2005) Surv ophthalmol. Jul-Aug 50(4):351\u2013363. https:\/\/doi.org\/10.1016\/j.survophthal.2005.04.001","journal-title":"Jul-Aug"},{"issue":"1","key":"494_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3109\/09273948.2015.1032308","volume":"24","author":"R Agrawal","year":"2016","unstructured":"Agrawal R, Lee CS, Gonzalez-Lopez JJ, Khan S, Rodrigues V, Pavesio C (2016) Flurbiprofen: A nonselective cyclooxygenase (COX) inhibitor for treatment of noninfectious, Non-necrotizing anterior scleritis. Ocul Immunol Inflamm 24(1):35\u201342. https:\/\/doi.org\/10.3109\/09273948.2015.1032308","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"494_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ophtha.2011.07.043","volume":"119","author":"M de la Sainz","year":"2012","unstructured":"de la Sainz M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS (2012) Scleritis therapy. Ophthalmol Jan 119(1):51\u201358. https:\/\/doi.org\/10.1016\/j.ophtha.2011.07.043","journal-title":"Ophthalmol Jan"},{"issue":"2","key":"494_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/APO.0000000000000341","volume":"7","author":"P Dutta Majumder","year":"2020","unstructured":"Dutta Majumder P, Agrawal R, McCluskey P, Biswas J (2020) Current approach for the diagnosis and management of noninfective scleritis. Asia Pac J Ophthalmol (Phila) Dec 7(2):212\u2013223. https:\/\/doi.org\/10.1097\/APO.0000000000000341","journal-title":"Asia Pac J Ophthalmol (Phila) Dec"},{"issue":"4","key":"494_CR12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/s0002-9394(00)00659-0","volume":"130","author":"DA Jabs","year":"2000","unstructured":"Jabs DA, Rosenbaum JT, Foster CS et al (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol Oct 130(4):492\u2013513. https:\/\/doi.org\/10.1016\/s0002-9394(00)00659-0","journal-title":"Am J Ophthalmol Oct"},{"issue":"1","key":"494_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2015.07.001","volume":"61","author":"CS Foster","year":"2016","unstructured":"Foster CS, Kothari S, Anesi SD et al (2016) The ocular immunology and uveitis foundation preferred practice patterns of uveitis management. Surv Ophthalmol Jan-Feb 61(1):1\u201317. https:\/\/doi.org\/10.1016\/j.survophthal.2015.07.001","journal-title":"Surv Ophthalmol Jan-Feb"},{"issue":"6","key":"494_CR14","first-page":"1138","volume":"38","author":"C Fabiani","year":"2020","unstructured":"Fabiani C, Sota J, Sainz-de-la-Maza M et al (2020) Effectiveness of TNF-alpha Blockade in the treatment of refractory non-infectious scleritis: a multicentre study. Clin Exp Rheumatol Nov-Dec 38(6):1138\u20131144","journal-title":"Clin Exp Rheumatol Nov-Dec"},{"issue":"10","key":"494_CR15","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/j.ophtha.2014.04.044","volume":"121","author":"EB Suhler","year":"2014","unstructured":"Suhler EB, Lim LL, Beardsley RM et al (2014) Rituximab therapy for refractory scleritis: results of a phase I\/II dose-ranging, randomized, clinical trial. Ophthalmol Oct 121(10):1885\u20131891. https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.044","journal-title":"Ophthalmol Oct"},{"issue":"1","key":"494_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ajo.2009.07.035","volume":"149","author":"KS Johnson","year":"2010","unstructured":"Johnson KS, Chu DS (2010) Evaluation of sub-Tenon triamcinolone acetonide injections in the treatment of scleritis. Am J Ophthalmol Jan 149(1):77\u201381. https:\/\/doi.org\/10.1016\/j.ajo.2009.07.035","journal-title":"Am J Ophthalmol Jan"},{"issue":"6","key":"494_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1136\/bjo.2009.164962","volume":"94","author":"A Roufas","year":"2010","unstructured":"Roufas A, Jalaludin B, Gaskin C, McCluskey P (2010) Subconjunctival triamcinolone treatment for non-necrotising anterior scleritis. Br J Ophthalmol Jun 94(6):743\u2013747. https:\/\/doi.org\/10.1136\/bjo.2009.164962","journal-title":"Br J Ophthalmol Jun"},{"issue":"10","key":"494_CR18","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.ophtha.2011.02.043","volume":"118","author":"EH Sohn","year":"2011","unstructured":"Sohn EH, Wang R, Read R et al (2011) Long-term, multicenter evaluation of subconjunctival injection of triamcinolone for non-necrotizing, noninfectious anterior scleritis. Ophthalmol Oct 118(10):1932\u20131937. https:\/\/doi.org\/10.1016\/j.ophtha.2011.02.043","journal-title":"Ophthalmol Oct"},{"issue":"4","key":"494_CR19","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/s0161-6420(01)01018-1","volume":"109","author":"E Zamir","year":"2002","unstructured":"Zamir E, Read RW, Smith RE, Wang RC, Rao NA (2002) A prospective evaluation of subconjunctival injection of triamcinolone acetonide for resistant anterior scleritis. Ophthalmol Apr 109(4):798\u2013805 discussion 805-7. https:\/\/doi.org\/10.1016\/s0161-6420(01)01018-1","journal-title":"Ophthalmol Apr"},{"key":"494_CR20","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2147\/OPTH.S209395","volume":"16","author":"K Kishore","year":"2022","unstructured":"Kishore K, Bhat PV, Venkatesh P, Canizela CC (2022) Dexamethasone intravitreal implant for the treatment of macular edema and uveitis: A comprehensive narrative review. Clin Ophthalmol 16:1019\u20131045. https:\/\/doi.org\/10.2147\/OPTH.S209395","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"494_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1869-5760-3-7","volume":"7","author":"H Nascimento","year":"2013","unstructured":"Nascimento H, Franca M, Garcia LG, Muccioli C, Belfort R (2013) Jr. Subconjunctival dexamethasone implant for non-necrotizing scleritis. J Ophthalmic Inflamm Infect Jan 7(1):7. https:\/\/doi.org\/10.1186\/1869-5760-3-7","journal-title":"J Ophthalmic Inflamm Infect Jan"},{"issue":"2","key":"494_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/bjophthalmol-2021-319376","volume":"107","author":"MC Trone","year":"2023","unstructured":"Trone MC, Poinard S, Crouzet E et al (2023) Dropless penetrating keratoplasty using a subconjunctival dexamethasone implant: safety pilot study. Br J Ophthalmol Feb 107(2):181\u2013186. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-319376","journal-title":"Br J Ophthalmol Feb"},{"issue":"12","key":"494_CR23","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1097\/ICO.0b013e3182a407c3","volume":"32","author":"G Honik","year":"2013","unstructured":"Honik G, Wong IG, Gritz DC (2013) Incidence and prevalence of episcleritis and scleritis in Northern California. Cornea Dec 32(12):1562\u20131566. https:\/\/doi.org\/10.1097\/ICO.0b013e3182a407c3","journal-title":"Cornea Dec"},{"issue":"6","key":"494_CR24","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.survophthal.2016.06.002","volume":"61","author":"J Daniel Diaz","year":"2016","unstructured":"Daniel Diaz J, Sobol EK, Gritz DC (2016) Treatment and management of scleral disorders. Surv ophthalmol. Nov-Dec 61(6):702\u2013717. https:\/\/doi.org\/10.1016\/j.survophthal.2016.06.002","journal-title":"Nov-Dec"},{"issue":"5","key":"494_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","volume":"129","author":"C Lowder","year":"2011","unstructured":"Lowder C, Belfort R Jr., Lightman S et al (2011) Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol May 129(5):545\u2013553. https:\/\/doi.org\/10.1001\/archophthalmol.2010.339","journal-title":"Arch Ophthalmol May"},{"issue":"4","key":"494_CR26","first-page":"317","volume":"6","author":"N Haghjou","year":"2011","unstructured":"Haghjou N, Soheilian M, Abdekhodaie MJ (2011) Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res Oct 6(4):317\u2013329","journal-title":"J Ophthalmic Vis Res Oct"},{"issue":"1","key":"494_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12348-019-0189-4","volume":"10","author":"SS Saincher","year":"2020","unstructured":"Saincher SS, Gottlieb C (2020) Ozurdex (dexamethasone intravitreal implant) for the treatment of intermediate, posterior, and panuveitis: a systematic review of the current evidence. J Ophthalmic Inflamm Infect Jan 10(1):1. https:\/\/doi.org\/10.1186\/s12348-019-0189-4","journal-title":"J Ophthalmic Inflamm Infect Jan"},{"key":"494_CR28","doi-asserted-by":"publisher","unstructured":"Valizadeh G, Manta AI, Conrad D, Schlect D, Sullivan TJ Granulomatosis with polyangiitis-associated sclerokeratitis in a case of ocular adnexal B-cell lymphoma. Orbit Jan 30 2023:1\u20133. https:\/\/doi.org\/10.1080\/01676830.2023.2172191","DOI":"10.1080\/01676830.2023.2172191"},{"key":"494_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40942-018-0114-2","volume":"4","author":"SK Mishra","year":"2018","unstructured":"Mishra SK, Gupta A, Patyal S et al (2018) Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety. Int J Retina Vitreous 4:13. https:\/\/doi.org\/10.1186\/s40942-018-0114-2","journal-title":"Int J Retina Vitreous"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00494-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-025-00494-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00494-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T05:01:05Z","timestamp":1746507665000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-025-00494-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["494"],"URL":"https:\/\/doi.org\/10.1186\/s12348-025-00494-6","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local institutional review board at Stanford University approved the study, and an informed consent waiver was obtained as the charts of enrolled patients were retrospectively reviewed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All presentations of case reports have written consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr Quan Dong Nguyen is an Editorial Board member of the journal. The rest of the authors have no conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}